AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
2.620
-0.140 (-5.07%)
At close: Oct 27, 2025, 4:00 PM EDT
2.620
0.00 (0.00%)
After-hours: Oct 27, 2025, 6:30 PM EDT
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $25.00K in the quarter ending June 30, 2025, a decrease of -50.00%. This brings the company's revenue in the last twelve months to $121.00K, down -39.80% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.
Revenue (ttm)
$121.00K
Revenue Growth
-39.80%
P/S Ratio
59.09
Revenue / Employee
$5,261
Employees
23
Market Cap
7.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AIM News
- 7 days ago - AIM ImmunoTech to Attend the 2025 Maxim Growth Summit - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors - GlobeNewsWire
- 7 weeks ago - AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 2 months ago - AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - GlobeNewsWire
- 3 months ago - AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval - GlobeNewsWire